# File Descriptions

All datasets are formatted to contain antibody variable domain sequence (heavy chain + light chain or heavy chain only), and one or more fitness metric.

| filename | size | assay/units | description | publication | year |
| -------- | ---- | ----------- | ----------- | ----------- | ---- |
| jain2017biophyscial_HICRT.csv | 137 | HIC Retention Time (Min)a | Clinical stage therapeutic antibodies | [Biophysical properties of the clinical-stage antibody landscape](https://doi.org/10.1073/pnas.1616408114) | 2017 |
| jain2017biophysical_ACSINS.csv | 137 | Affinity-Capture Self-Interaction Nanoparticle Spectroscopy (AC-SINS) ∆λmax (nm) Average | Clinical stage therapeutic antibodies | [Biophysical properties of the clinical-stage antibody landscape](https://doi.org/10.1073/pnas.1616408114) | 2017 |
| jain2017biophysical_CSIBLI.csv | 137 | CSI-BLI Delta Response (nm) | Clinical stage therapeutic antibodies | [Biophysical properties of the clinical-stage antibody landscape](https://doi.org/10.1073/pnas.1616408114) | 2017 |
| jain2017biophysical_SAS.csv | 137 | Slope for Accelerated Stability | Clinical stage therapeutic antibodies | [Biophysical properties of the clinical-stage antibody landscape](https://doi.org/10.1073/pnas.1616408114) | 2017 |
| jain2017biophysical_SGACSINS.csv | 137 | SGAC-SINS AS100 ((NH4)2SO4 mM) | Clinical stage therapeutic antibodies | [Biophysical properties of the clinical-stage antibody landscape](https://doi.org/10.1073/pnas.1616408114) | 2017 |
| jain2024assessment_ACSINS.csv | 43 | AC-SINS ∆λmax (nm) | Germline Fv antibodies | [Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows](https://doi.org/10.1080/19420862.2024.2384104) | 2024 |
| jain2024assessment_CIC.csv | 43 | CIC Column K | Germline Fv antibodies | [Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows](https://doi.org/10.1080/19420862.2024.2384104) | 2024 |
| jain2024assessment_CSSINS.csv | 43 | CS-SINS (ave) | Germline Fv antibodies | [Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows](https://doi.org/10.1080/19420862.2024.2384104) | 2024 |
| jain2024assessment_Fab_pI.csv | 43 | Fab.pI | Germline Fv antibodies | [Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows](https://doi.org/10.1080/19420862.2024.2384104) | 2024 |
| jain2024assessment_HIC.csv | 43 | HIC RT (min) | Germline Fv antibodies | [Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows](https://doi.org/10.1080/19420862.2024.2384104) | 2024 |
| jain2024assessment_SEC.csv | 43 | SEC % Monomer | Germline Fv antibodies | [Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows](https://doi.org/10.1080/19420862.2024.2384104) | 2024 |
| jain2024assessment_cIEF.csv | 43 | cIEF Main peak | Germline Fv antibodies | [Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows](https://doi.org/10.1080/19420862.2024.2384104) | 2024 |
| jetha2019homology_RT.csv | 97 | HIC RT (min) | Integrin α11 Fv antibodies | [Homology modeling and structure-based design improve hydrophobic interaction chromatography behavior of integrin binding antibodies](https://doi.org/10.1080/19420862.2018.1475871) | 2018 |
| kraft2019herapin_relrt.csv | 128 | Heparin retention time (min) | Clinical stage therapeutic antibodies | [Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis](https://doi.org/10.1080/19420862.2019.1683432) | 2019 |
| shanehsazzadeh2023unlocking_ACSINS.csv | 13 | AC-SINS - Shift (nm) | Trastuzumab Fv antibodies | [Unlocking de novo antibody design with generative artificial intelligence](https://doi.org/10.1101/2023.01.08.523187) | 2024 |
| shanehsazzadeh2023unlocking_CGE.csv | 13 | Red-CGE - Purity (%) | Trastuzumab Fv antibodies | [Unlocking de novo antibody design with generative artificial intelligence](https://doi.org/10.1101/2023.01.08.523187) | 2024 |
| shanehsazzadeh2023unlocking_HICRRT.csv | 13 | HIC - RRT | Trastuzumab Fv antibodies | [Unlocking de novo antibody design with generative artificial intelligence](https://doi.org/10.1101/2023.01.08.523187) | 2024 |
| shanehsazzadeh2023unlocking_NRCGE.csv | 13 | NR-CGE - Main (%) | Trastuzumab Fv antibodies | [Unlocking de novo antibody design with generative artificial intelligence](https://doi.org/10.1101/2023.01.08.523187) | 2024 |
| shanehsazzadeh2023unlocking_SEC.csv | 13 | SEC - Main (%) | Trastuzumab Fv antibodies | [Unlocking de novo antibody design with generative artificial intelligence](https://doi.org/10.1101/2023.01.08.523187) | 2024 |


# Additional data not included

`Ginkgo Datapoints developability assays` - https://datapoints.ginkgo.bio/what-we-do/antibody-developability




